A HANC Risk Stratification Score for Antiplatelet Therapy Optimization with Low-Dose Prasugrel in Taiwanese Acute Coronary Syndrome Patients from the Switch Study

Lee, Wen-LiengWen-LiengLeeYI-CHIH WANGSu, Chieh-ShouChieh-ShouSuLee, Hsin-FuHsin-FuLeeTung, Ying-ChangYing-ChangTungLiu, Ping-YenPing-YenLiuSu, Cheng-HuangCheng-HuangSuKuo, Feng-YuFeng-YuKuoLin, Wei-ShiangWei-ShiangLinChu, Pao-HsienPao-HsienChuLu, Tse-MinTse-MinLuLo, Ping-HanPing-HanLoTsukiyama, ShujiShujiTsukiyamaYang, Wei-ChenWei-ChenYangCheng, Li-ChungLi-ChungChengYin, Wei-HsianWei-HsianYinYEN-HUNG LIN2023-03-102023-03-102022-111011-6842https://scholars.lib.ntu.edu.tw/handle/123456789/629200A significant proportion of acute coronary syndrome (ACS) patients experience high on-treatment platelet reactivity (HPR) on clopidogrel-based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).enAcute coronary syndrome; CYP2C19; Clopidogrel; Dual anti-platelet therapy; East Asian paradox; High on-treatment platelet reactivity; Prasugrel; Risk stratification[SDGs]SDG3A HANC Risk Stratification Score for Antiplatelet Therapy Optimization with Low-Dose Prasugrel in Taiwanese Acute Coronary Syndrome Patients from the Switch Studyjournal article10.6515/ACS.202211_38(6).20220702A364402502-s2.0-85141882620WOS:000898856800009